Clinical trials for anti-CTLA-4 and anti-PD-1 combinational therapy have demonstrated promising anti-tumor activity in lung cancers, mesothelioma, esophagogastric cancer, prostate cancer, and sarcoma [108,109,110,111,112,113]. Here, CTLA4 is linked to Familial prostate cancer.